Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:administeredBy |
gptkb:tablet
|
| gptkbp:approvedBy |
gptkb:Japan
2014 |
| gptkbp:ATCCode |
J05AX27
|
| gptkbp:brand |
gptkb:Avigan
|
| gptkbp:chemicalFormula |
C5H4FN3O2
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:countryOfOrigin |
gptkb:Japan
|
| gptkbp:developedBy |
gptkb:Toyama_Chemical
|
| gptkbp:genericName |
favipiravir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avigan
|
| gptkbp:investigatedBy |
gptkb:COVID-19
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
Fujifilm Toyama Chemical
|
| gptkbp:mechanismOfAction |
RNA polymerase inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
teratogenicity
liver enzyme elevation elevated uric acid |
| gptkbp:usedFor |
influenza
|
| gptkbp:bfsParent |
gptkb:Favipiravir
|
| gptkbp:bfsLayer |
7
|